MarketBeat
13 Aug 2026, 05:02 UTC · 2h ago
Castle Biosciences Raises Outlook as Melanoma, TissueCypher Tests Gain Traction
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
MarketBeat
13 Aug 2026, 05:02 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
6 claims · each scored for market impact
Castle Biosciences raised its full-year outlook by an amount exceeding its second-quarter earnings beat. — Raising guidance following a beat signals strong fundamental momentum and management confidence in second-half performance.
+0.60TissueCypher has only 15% patient penetration, implying the business could more than double if it reaches levels similar to the melanoma test. — Significant untapped market share in a core product provides a clear path for substantial organic revenue growth.
+0.50The company expects to remain adjusted EBITDA positive through 2026 and into 2027. — Confirmed profitability thresholds reduce financial risk and improve the company's valuation profile.
+0.40Continue reading
6 related stories
Top 1 mover · tap to explore
Castle is seeking FDA clearance for its melanoma test to potentially strengthen reimbursement and prevent insurers from classifying it as experimental. — FDA clearance serves as a catalyst for better payer coverage and reduced reimbursement friction.
+0.30Which stocks this story touches
The company reported continued momentum, raised its financial outlook, and demonstrated growth across its core diagnostic franchises.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
2h ago
